CardioDx, a Palo Alto, Calif.-based developer of cardiovascular genomic diagnostics, has raised $5m as part of a Series D round of funding.
The investment was made by the GE Healthymagination Fund, which is focused on highly promising healthcare technology companies. This is the first investment for the fund.
The capital will be used to advance and co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease.
CardioDx, develops genomic tests to aid in the assessment and tailoring of care of individuals with cardiovascular diseases such as coronary artery disease (CAD), cardiac arrhythmias and heart failure.
The company’s initial product, Corus™ CAD, is a clinically validated non-invasive genomic test that uses data such as gene expression levels and other patient characteristics to assess the likelihood that a patient has obstructive coronary artery disease (CAD) – a narrowing or blockage of the coronary arteries that can lead to heart attack or death. Corus CAD uses a blood test to quantify the likelihood of CAD, helping cardiologists make more informed decisions on how best to diagnose and treat their patients.
CardioDx is funded by Kleiner, Perkins, Caufield & Byers, TPG Biotech, Mohr Davidow Ventures, Intel Capital and Pappas Ventures.